Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NorthStar, YAP Therapeutics Partner to Develop & Manufacture Radiopharmaceuticals | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

NorthStar, YAP Therapeutics Partner to Develop & Manufacture Radiopharmaceuticals

NorthStar will provide non-carrier added actinium-225 (n.c.a. Ac-225) and offer CDMO services.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

NorthStar Medical Radioisotopes, LLC and YAP Therapeutics, Inc. have formed a partnership to develop and manufacture radiopharmaceuticals targeting cancer and other chronic illnesses.

As part of this collaboration, NorthStar will assist in the progression of YAP Therapeutics’ biologic products by providing non-carrier added actinium-225 (n.c.a. Ac-225) and offering its contract development and manufacturing (CDMO) services for radiopharmaceuticals. Moreover, NorthStar will also prepare doses of YAP Therapeutics’ investigational drugs that are ready for clinical trials. Once regulatory approval is obtained, NorthStar may produce and supply radionuclides for YAP Therapeutics’ commercial applications.

“NorthStar leads in medical radioisotope development and production. This agreement furthers our goal to deliver radiopharmaceuticals to patients,” said Frank Scholz, President and CEO of NorthStar. “We are excited to partner with YAP Therapeutics, merging our technology with their biologics to target specific therapies. Our ability to provide key radioisotopes like Ac-225 and CDMO capabilities offers substantial support to YAP Therapeutics.”

“We are thrilled about partnering with NorthStar to improve cancer treatment. Their radiopharmaceutical expertise complements our biologics development,” said Olav Bergheim, Founder and Chairman of YAP Therapeutics. “This partnership offers the potential to expand our rich pipeline with leading radioisotope technology.”

Related News

In December, NorthStar and Ariceum Therapeutics signed a supply agreement for actinium-225 (Ac-225).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics